X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indoco Remedies Fact Sheet, Indoco Remedies Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indoco Remedies Fact Sheet   (INDOCO)

Here is the latest financial fact sheet of Indoco Remedies. For more details, see the Indoco Remedies quarterly results and Indoco Remedies share price and chart. For a sector overview, read our pharmaceuticals sector report.

INDOCO REMEDIES Price History

Price Rs 265.2
Mkt Cap Rs m 24,440
Vol '000 17.5
P/E X 31.6
P/CF X 17.4
EPS (TTM) Rs 8.4
% ch % 1.8
No. of shares m 92.18
% ch week % -3.1
% ch 1-mth % -3.5
% ch 12-mth % 1.6
52 week H/L Rs 317.0/179.0
(As on Feb 16, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

INDOCO REMEDIES Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
INDOCO REMEDIES EQUITY SHARE DATA
High Rs83162378412360 
Low Rs5155131263249 
Sales per share (Unadj.) Rs68.579.593.0109.4119.0 
Earnings per share (Unadj.) Rs4.66.39.08.98.4 
Diluted earnings per shareRs4.66.39.08.98.4 
Cash flow per share (Unadj.) Rs7.29.614.115.515.2 
Dividends per share (Unadj.) Rs1.101.401.601.601.60 
Adj. dividends per shareRs1.101.401.601.601.60 
Dividend yield (eoy) %1.61.30.60.50.5 
Book value per share (Unadj.) Rs44.949.657.362.670.7 
Adj. book value per shareRs44.949.657.362.570.7 
Shares outstanding (eoy) m92.1592.1592.1592.1592.15 
Bonus/Rights/Conversions  FV2, B1:2---- 
Price / Sales ratio x1.01.42.73.12.6 
Avg P/E ratio x14.517.228.337.936.4 
P/CF ratio (eoy) x9.311.218.021.820.0 
Price / Book Value ratio x1.52.24.45.44.3 
Dividend payout %23.722.217.818.019.1 
Avg Mkt Cap Rs m6,1749,98923,43831,08728,083 
No. of employees `000NANANA5.76.0 
Total wages/salary Rs m1,0791,2951,4001,8192,167 
Avg. sales/employee Rs ThNMNMNM1,762.41,817.0 
Avg. wages/employee Rs ThNMNMNM318.0359.0 
Avg. net profit/employee Rs ThNMNMNM143.3127.7 
INDOCO REMEDIES INCOME DATA
Net Sales Rs m6,3087,3268,57010,08110,968 
Other income Rs m1518171640 
Total revenues Rs m6,3237,3448,58710,09711,007 
Gross profit Rs m9261,2041,6551,7041,565 
Depreciation Rs m237309471607633 
Interest Rs m21918910612462 
Profit before tax Rs m4867231,096989909 
Minority Interest Rs m0-1000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m58143267170139 
Profit after tax Rs m427580828819771 
Gross profit margin %14.716.419.316.914.3 
Effective tax rate %11.919.824.417.215.3 
Net profit margin %6.87.99.78.17.0 
INDOCO REMEDIES BALANCE SHEET DATA
Current assets Rs m2,7553,0463,8904,6465,725 
Current liabilities Rs m1,9932,0222,9263,6415,454 
Net working cap to sales %12.114.011.310.02.5 
Current ratio x1.41.51.31.31.0 
Inventory Days Days5455646062 
Debtors Days Days7469666872 
Net fixed assets Rs m3,5923,6944,0224,2965,307 
Share capital Rs m184184184184184 
"Free" reserves Rs m3,9504,3805,0935,5816,331 
Net worth Rs m4,1424,5725,2775,7656,516 
Long term debt Rs m2741381293791,323 
Total assets Rs m6,9197,2948,2039,40611,970 
Interest coverage x3.24.811.49.015.6 
Debt to equity ratio x0.1000.10.2 
Sales to assets ratio x0.91.01.01.10.9 
Return on assets %9.310.511.410.07.0 
Return on equity %10.312.715.714.211.8 
Return on capital %15.919.422.218.112.4 
Exports to sales %33.533.936.240.10 
Imports to sales %5.45.47.57.70 
Exports (fob) Rs m2,1162,4803,1014,0440 
Imports (cif) Rs m3433966437730 
Fx inflow Rs m2,1162,4803,1014,0444,507 
Fx outflow Rs m4455498191,0171,141 
Net fx Rs m1,6711,9312,2823,0273,366 
INDOCO REMEDIES CASH FLOW
From Operations Rs m 687 988 1,090 1,122 886 
From Investments Rs m -426 -410 -884 -1,107 -1,706 
From Financial Activity Rs m -244 -590 -199 -16 1,316 
Net Cashflow Rs m 17 -12 7 -1 497 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 59.2%
Foreign collaborators 0.0%
Indian inst/Mut Fund 12.5%
FIIs 6.0%
ADR/GDR 0.0%
Free float 22.4%
Shareholders 12,805
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 166, Indoco House, CST Road, kalina, Santacruz (E), Mumbai - 400 098
E-MAIL sunil.joshi@indoco.com WEB www.indoco.com
TELEPHONE (022) 2654 1851 FAX (022) 2652 3067
SECTOR MISCELLANEOUS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Patkar & Pendse
CHM: Suresh G. Kare (MD) COMP SEC: Sunil D. Joshi YEAR OF INC: 1945 BSE CODE: 532612 FV (Rs): 2 DIV YIELD (%): 0.6

More Miscellaneous Company Fact Sheets:   J.B.CHEMICALS  GLENMARK PHARMA  CADILA HEALTHCARE  ORCHID PHARMA LTD  FULFORD INDIA  

Compare INDOCO REMEDIES With:   J.B.CHEMICALS  GLENMARK PHARMA  CADILA HEALTHCARE  ORCHID PHARMA LTD  FULFORD INDIA  

Compare INDOCO REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - RELIGARE ENT. COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS